Replies to post #767109 on NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

DD, What a great job of pulling together the history of the Czech trial and how NWBO came to acquire it.
I have one question: Did any money exchange hands? In the end, did NWBO buy them or in-license the university's trial and its body of work? Or was it more like, "hey, your work falls under our patent, so we own you now?"
And now we have (most likely in the near future) tissue agnostic designation.

What a visionary Linda Powers is! I shouldn't be surprised. We all know her background in patent work. And we all know that however hard we try to guess what's going on behind the curtain, she always comes up with something better than any one of us could have imagined !

[hankmanhub]

DD, this was a great post. There is one point that I do not understand. If initially the Czechs were already investigating this before NWBO had a patent, how did NWBO ever obtain a patent if there was already prior research on this by the Czechs?

[Chiugray]

TDD, Your post started me on a deep dive. I am realizing that NWBO’s acquisition of Roswell's IP was a much bigger strategic and pivotal move than I originally thought. It enables NWBO to have more solid tumor-agnostic rights in DCs.

Roswell Center owned patents on the use of IL-12, IFN-y, and TLR agonists (ie Poly ICLC/Hiltonol) to mature dendritic cells. NWBO had previously licensed portions of IP from Dr. Kalinski prior to him coming to Roswell.

Therefore, pre-Roswell acquisition, in a commercial setting:
• DCVax-L + Hiltonol (poly-ICLC) could have been seen as a potential infringement, outside of glioblastoma
• Means that NWBO would have been restricted from making any tumor-agnostic claims (ie say that the same benefits in GBM works the same way in other cancers). They would need the underlying IP rights for broad application.

Post-acquisition of exclusive in-licensing of all Roswell’s DC IP, NWBO is now fully protected.

NWBO now holds the core IP. Effectively it now holds the dominant Freedom to Operate (FTO) position:
• especially in the tumor-agnostic dendritic cell vaccine space
• especially for DCVax-L + poly-ICLC
Needless to say, these are both very important.

Connecting dots with other events. Previously I saw these as coincidences, but maybe they are instead the benefits from the Roswell acquisition already beginning to materialize:

Czechia (Masaryk University) pediatric trial
• Rebranded its multiple cancer pediatric trial name from MyDendrix to Murcidencel (DCVax-L)
• Probably realized their IP now overlapped with patents held by NWBO.
• Positive pediatric trial data across multiple cancer types could support broader, tumor agnostic claims for NWBO
• As a result, this trial’s results will merge into NWBO’s IP portfolio, aid in its regulatory submissions, and will save years of time and money.

The UK’s NHS changed the indication for Murcidencel from GBM to Cancer (much broader).
• NWBO acquisition of Roswell’s patents June 2024 gave it broader IP protection to make that change.